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Stats (signal transducers and activators of transcription) are latent cytoplasmic transcription
factors that on a specific stimulus migrate to the nucleus and exert their transcriptional activity.
Here we report a novel signaling pathway whereby RhoA can efficiently modulate Stat3 tran-
scriptional activity by inducing its simultaneous tyrosine and serine phosphorylation. Tyrosine
phosphorylation is exerted via a member of the Src family of kinases (SrcFK) and JAK2, whereas
the JNK pathway mediates serine phosphorylation. Furthermore, cooperation of both tyrosine as
well as serine phosphorylation is necessary for full activation of Stat3. Induction of Stat3 activity
depends on the effector domain of RhoA and correlates with induction of both Src Kinase-related
and JNK activities. Activation of Stat3 has biological implications. Coexpression of an oncogenic
version of RhoA along with the wild-type, nontransforming Stat3 gene, significantly enhances its
oncogenic activity on human HEK cells, suggesting that Stat3 is an essential component of
RhoA-mediated transformation. In keeping with this, dominant negative Stat3 mutants or inhi-
bition of its tyrosine or serine phosphorylation completely abrogate RhoA oncogenic potential.
Taken together, these results indicate that Stat3 is an important player in RhoA-mediated onco-
genic transformation, which requires simultaneous phosphorylation at both tyrosine and serine
residues by specific signaling events triggered by RhoA effectors.
INTRODUCTION
Rho GTPases are members of the Ras superfamily involved in
critical cellular functions such as cell growth, development,
apoptosis, and cell cytoarchitecture as well as in dysregulatory
scenarios such as tumorigenesis and metastasis (Narumiya,
1996; Van Aelst and D’Souza-Schorey, 1997; Herna´ndez-Alco-
ceba et al., 2000). Although much is known about the pathways
that lead to Rho-mediated transformation, the precise mecha-
nisms by which these proteins impinge in regulation of cell
proliferation and the subversion that takes place during cell
transformation need further in depth study.
It is well established that members of this family of small
GTPases induce the activation of intracellular signaling cas-
cades that result in the activation of specific transcription
factors. Thus, constitutively active forms of Cdc42Hs and
Rac1 can effectively induce the activity of c-Jun N-terminal
kinase/stress-activated protein kinases (JNK/SAPK; Coso et
al., 1995; Minden et al., 1995). As well, constitutively acti-
vated mutants of Rac1 and Cdc42Hs induce p38/Mpk2 ac-
tivity (Coso et al., 1995). Interestingly, in human embryonic
kidney (HEK)-293T cells, RhoA, RhoB, RhoC, and Cdc42Hs,
but not Rac1, can activate this kinase (Teramoto et al., 1996).
In addition, in human epithelial A459, RhoA is involved in
JNK activation in response to specific stimuli (Roberts et al.,
1998), suggesting that RhoA might regulate this MAPK in
diverse human cell lines.
We have previously described the activation of the nu-
clear factor B (NF-B) by prototypes of the three families of
Rho GTPases: RhoA, Rac1, and Cdc42Hs (Perona et al., 1997;
Montaner et al., 1998, 1999). This activation was also ob-
served by different members of the family of exchange fac-
tors for Rho proteins (Dbl family), mainly Vav, Ost, and Dbl.
Furthermore, the JNK/SAPK cascade is involved in this
pathway for Rac1 and Cdc42Hs, but not for RhoA. Recently,
Zohar et al. (1998) and Sahai et al. (1998) have shown that
effector domains within Rho GTPases that are responsible
for nuclear signaling and cellular transformation are inde-
pendent of those involved in cytoskeletal rearrangement
functions. Yet, there still is some controversy in this topic
because SRF activation by Rho GTPases appears to be linked
to actin dynamics (Hill et al., 1995; Sotiropoulos et al., 1999).
Furthermore, little is known about the physiological roles of
these domains and the effectors they interact with.* Corresponding author. E-mail address: jclacal@iib.uam.es.
3282 © 2001 by The American Society for Cell Biology
Stats are a family of transcription factors implicated in
ligand-dependent growth stimulation or differentiation as
well as in antiproliferative effects (Darnell, 1997; Schindler,
1998). Although Stats transcription factors were originally
identified as components of a DNA-bound complex induced
by IFN- stimulus (Shuai et al., 1992), nowadays it is known
that 40 different extracellular polypeptides that activate
either receptor tyrosine kinases (RTKs) or cytokine receptors
coupled to JAKs trigger Stats activation. Seven mammalian
Stat genes have been identified so far, arranged in three
chromosomal clusters, and alternative splicing leads to the
synthesis of additional Stats. On cytokine stimulation, JAKs
are recruited to the oligomerized receptor, phosphorylating
it at specific residues that constitute docking sites for Stat
monomers (Heim et al., 1995; Stahl et al., 1995). Once re-
cruited to the receptor via their src homology domain-2
(SH-2), Stats are phosphorylated by JAKs on a single ty-
rosine in the C terminus at position 705. This phosphoryla-
tion event enables Stats to homo- or heterodimerize, via
their SH2 domains to subsequently migrate to the nucleus
where they interact with both DNA motifs located at the
promoter region of specific genes as well as other transcrip-
tion factors and accessory proteins, thereby stimulating tran-
scription (Paulson et al., 1999).
A second phosphorylation event in a single serine (resi-
due 727) has been described recently that modulates tran-
scriptional activity of Stat3 (Sadowski et al., 1993; Ram et al.,
1996; Wen et al., 1997; Kuroki et al., 1999). Members of the
MAPK and JNK family of serine kinases mediate this serine
phosphorylation. Serine phosphorylation appears to be in
some cases necessary for maximal transcriptional activity of
Stat3 (Ng and Cantrell, 1997; Sengupta et al., 1998), whereas
inhibitory in others (Chung et al., 1997; Jain et al., 1998; Lim
and Cao, 1999; Woetmann et al., 1999). Furthermore, serine
phosphorylation does not seem to be necessary for DNA
binding (Wen and Darnell, 1997), and some works have
described no DNA binding activity upon serine phosphor-
ylation (Ceresa and Pessin, 1996).
Here, we investigate the functional relationship between
Rho proteins and Stat3 transcription factor and its biological
implications. With the use of human HEK-293T cells we
demonstrate that RhoA and to a lesser extent Cdc42Hs, but
not Rac1, can efficiently activate Stat3 transcriptional activity
by both tyrosine and serine phosphorylation. As well, RhoA
can induce Stat3 activity in other cell systems such as CHO-4
and BRL-4 cells. We provide evidence of a role for a member
of the Src family kinase and JAK2 in Stat3 tyrosine phos-
phorylation and of JNK1 cascade in Stat3 serine phosphor-
ylation upon Rho activation. Finally, we demonstrate that
Stat3 cooperates with RhoA for the oncogenic transforma-
tion of human cells and might be necessary for RhoA-me-
diated transformation.
EXPERIMENTAL PROCEDURES
Cell Culture, Transfections, and Chemical Inhibitors
Human embryonic kidney 293T fibroblast cells (HEK293T), Chinese
Hamster Ovary 4 cells (CHO4), and Buffalo Rat Liver cells (BRL),
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FCS) and 1 mM glu-
tamine. For transient expression assays, 4–8  105 HEK293T or
CHO4 cells were transfected in 60-mm dishes by the calcium phos-
phate method as described previously (Montaner et al., 1998). The
amount of plasmidic DNA was kept constant at 1–1.5 g per 60-mm
plate with the corresponding empty vector. BRL4 cells were trans-
fected by Lipofectamine Plus (Life Technologies BRL, Rockville,
MD) after the manufacturer’s manual. p38 inhibitor SB203580 (Cal-
biochem) and MEK1 inhibitor PD98059 (Calbiochem, La Jolla, CA)
were used at a final concentration of 20 and 50 M, respectively.
cSrc-specific inhibitor PP1 (Alexis, San Diego, CA) was resuspended
in DMSO and used at a final concentration of 10 M. JAK2 specific
inhibitor AG-490 (Calbiochem) was resuspended in DMSO and
added at the indicated concentrations.
Plasmids
pCDNAIIIB plasmid (Invitrogen, San Diego, CA) and derived ex-
pression vectors encoding for constitutively activated RhoA (QL),
Rac1 (QL), and Cdc42Hs (QL) proteins and their wild-type versions
have been described (Montaner et al., 1998). RhoA QL effector loop
mutants were kindly provided by Dr. Gutkind. The 1  SIE-CAT
(TTCCCGTCAA) contains the sequence of the human c-fos pro-
moter spanning from nucleotides 350/336 inserted into a
pBLCAT5 derived plasmid. The pfosCAT and the mutated version
in the SIE element were kindly provided by Dr. Ugo Moens. HIV-
LUC, 4SRECAT, Gal4-LUC, Gal4-c-jun reporter plasmids as well
as MEKK1-KR expression vector have been reported previously
(Montaner et al., 1998). PLNCX-vSrc plasmid and pXEM-Lckwt and
Lck Y505F were obtained from Dr. Crespo. Expression vector for
dominant negative JAK2 (pRk-JAK2-KE) was a kind gift from Dr.
I. M. Kerr. The JNK-1 binding domain (JBD) of JIP-1 spanning
residues 127–281, termed JIP-1 Dom. Neg (DN) was subcloned into
pXCXCMV expression plasmid. Dominant negative mutants of
Stat3 were generated and generously provided by Dr. Masahiko
Hibi.
Gene Expression Analysis
Cells, 8  105, were transfected with the indicated plasmids. Twen-
ty-four hours after transfection, protein extracts were prepared by
lysis with the commercially available reporter lysis buffer (Promega,
Madison, WI). The total amount of protein was determined with a
commercial kit based on the Bradford method (Bio-Rad, Richmond,
CA). Two to 4 g of protein was assayed for chloranphenicol acetyl
transferase (CAT) activity with the use of a xylene-based method.
Total volume of each cellular extract was adjusted to 85 l with 0.25
M Tris-HCl, pH 7.5, to which 40 l of a mixture containing 32 l 0.25
M Tris-HCl, 5 l butyryl CoA (5 mg/ml), 3 l 14C-chloranphenicol
(0.1 mCi/ml) was added. The reaction mixture was incubated for
1–2 h at 37°C, and the reaction was stopped by adding 300 l of a
mixture of 2:1, 2,6,10,14-tetramethylpentadecane (Pristane; Sigma
Chemical Co., St. Louis, MO):xylene isomers (Sigma). The mixture
was shaken vigorously for 30 s and spun at 14,000 rpm for 5 min.
Two hundred microliters of the upper phase was taken and added
to 4 ml of Optiphase Highsafe 2 liquid scintillation cocktail (Wal-
lack). Total counts (cpm) were detected with the use of a 1214
RackBeta Liquid scintillation counter (Wallack) and normalized by
microgram of protein. Luciferase activity derived from the transfec-
tion of the HIVLUC or Gal4-LUC/Gal4-c-jun reporters was detected
with the use of 100–400 ng of protein with a commercial kit (Pro-
mega). Transfection efficiencies were corrected by cotransfection of
the pCMV-CAT plasmid or pCMV-Luc, for luciferase and CAT
experiments, respectively.
Western Blot Assays, Immunoprecipitations, and
Kinase Activity Assay
For protein expression assays, cells were transfected with the cor-
responding plasmids and incubated in DMEM 0.5% FCS for the next
24 h. The lysis was performed in a buffer containing 50 mM Tris-
HCl, pH 7.5, 5 mM EDTA, 0.5% Triton X-100, 0.5% sodium deoxy-
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cholate, 15 mM -glycerophosphate, 10 mM Na4P2O7, 200 M or-
thovanadate, 50 mM NaF, 20 g/ml leupeptin, 20 g/ml aprotinin,
and 1 mM phenylmethylsulfonyl fluoride. Ten micrograms of total
protein was analyzed by SDS-electrophoresis on 10% polyacryl-
amide gels (SDS-PAGE). After transfer of proteins to Immobilon-P
PVDF membrane (Millipore, Bedford, MA), the blots were incu-
bated with the corresponding antibodies. Immunocomplexes were
visualized by enhanced chemiluminescence detection (Amersham,
Arlington Heights, IL) with the use of a biotinylated anti-rabbit
antibody and streptavidin-peroxidase. Immunoprecipitation assays
were performed as follows: 200–500 g of total extracts were incu-
bated with 2 g of indicated antibody for 1 h at 4°C. Twenty
microliters of Protein G-agarose (resuspended in lysis buffer) was
added and incubated overnight at 4°C. Conjugates were pelleted by
centrifugation at 2500 rpm at 4°C and washed four times with lysis
buffer. Supernatant was discarded, and 40 l of Laemmli buffer was
added, boiled at 95°C for 5 min, and subjected to electrophoresis.
Antisera against Stat3, phospho-Stat3 (Tyr 705), and phospho-Stat3
(Ser 727) were purchased from New England Biolabs (Beverly, MA).
Mouse monoclonal anti phospho-p44/42 MAP kinase (Thr202/
Tyr204) and phospho p38 were purchased from New England Bio-
labs. JAK2- and c-Src–specific polyclonal antibodies were obtained
from Sigma. C-Lyn– and c-Lck–specific polyclonal antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). For
kinase activity assay, rabbit antiserum against p38 was used as
previously reported (Sa´nchez-Perez and Perona, 1999). The rabbit
polyclonal antibody specific to Src pY418, which is able to recognize
all members of the Src family of kinases, was purchased from
Biosource (Camarillo, CA).
Electrophoretic Mobility Shift Assays
For EMSA assays, cells were transfected with the corresponding
plasmids and incubated in DMEM 0.5% FBS for 24 h. Nuclear
extracts were obtained as described previously (10). Nuclear protein
was measured with a commercial kit based on the Bradford method
(Bio-Rad). Two micrograms of nuclear protein was then incubated
with 0.1 ng of SIE probe (20,000 cpm) or with unlabeled probe and
subjected to electrophoresis on a nondenaturing 4% acrylamide:
bisacrylamide gel (29:1; Bio-Rad).
Anchorage-independent Growth in Soft Agar
Cells, 8  105 (293T), in 60-mm dishes were transiently transfected
as indicated above with the indicated expression vectors. Twenty-
four hours posttransfection, cells were trypsinized and resuspended
in fresh medium. Anchorage-independent growth assay was per-
formed as previously described with the use of 40  105 cells
(Perona et al., 1993). After 3 weeks of incubation the medium was
absorbed, and 500 l of 0.005% Crystal Violet was added and
incubated for 1 h at 37°C. Plates were then washed once with 1
PBS and visualized under a microscope.
RESULTS
Rho Proteins Activate Transcription through SIE
Sites in Human Embryonic Kidney Cells
We asked whether Rho proteins are capable of stimulating
Stat3-dependent transcription. Because the c-fos promoter
contains a SIE element responsive to Stat3 and Stat1 adjacent
to the SRE, we used a reporter plasmid containing a single
SIE element obtained from the human c-fos promoter span-
ning from nucleotides350/336 inserted into a pBLCAT5-
derived plasmid, consequently named SIECAT. A sequence
analysis was carried out to verify that indeed no other
known element responsive to Rho GTPases was present in
this reporter.
Fibroblast-like HEK293T cells were cotransfected with the
SIE-CAT reporter together with expression vectors for con-
stitutively active mutants or the wild-type versions of RhoA,
Rac1, and Cdc42Hs (QL; Figure 1A). An eightfold induction
of the SIE reporter was obtained in RhoA QL transfectants
over control cells. Cdc42Hs QL induced the activation of
SIECAT fourfold less than RhoA QL, but no detectable
activity was obtained for Rac1 QL. SIE-dependent activation
was observed to be dose dependent for both RhoA and
Figure 1. Rho proteins activate Stat3-dependent transcription. (A)
Constitutively active mutants as well as their wild-type versions for
RhoA, and to a lesser extent Cdc42 Hs (QL) but not Rac1, induce
transcriptional activation of the SIECAT reporter. RhoA QL, Rac1
QL, Cdc42Hs QL (0.1 g), v-Src (0.3 g), or LckDP (1.0 g) were
cotransfected independently along with 0.5 g of SIECAT reporter.
(B) Oncogenic mutants of RhoA, Rac1, and Cdc42 induce SRE-
driven transcription in HEK293T to a similar extent. Same amounts
as in A of RhoA, Rac1, and Cdc42 QL mutants were transfected,
along with 0.5 g of the SRECAT reporter. (C) RhoA QL efficiently
induces SIE-dependent transcription in both BRL-4 and CHO4 cells.
SIECAT reporter (0.5 g) was cotransfected with RhoA QL (1.0 g
each). Data shown in this figure represent the mean of a single
experiment performed in triplicate SD and are representative of at
least five5 independent experiments with similar results.
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Cdc42Hs, but no activation was achieved with Rac1 even at
high doses of plasmid (our unpublished results). Further-
more, although to a lower magnitude, similar results where
observed for the wild-type versions. RhoA and to a lesser
extent Cdc42Hs induced transcriptional activity of the SIE
reporter, but not Rac1. As a positive control of reporter
activity, vectors encoding either the oncogene v-src or a
dominant positive mutant Lck with a Y505F mutation
(LckDP) were used.
To verify whether the differences observed in SIE-depen-
dent transcription triggered by RhoA, Rac1, and Cdc42 were
not due to differential expression of the vectors, we cotrans-
fected each expression vector along with a SRECAT reporter
plasmid responsive to SRF. Both RhoA and Rac1 induced
transactivation of the SRE element in HEK-293T cells to the
same extent, whereas Cdc42 was more efficient in doing so
(Figure 1B). Finally, a similar experiment was carried out
with respect to RhoA, with the use of two additional cell
lines, BRL-4 and CHO-4, with results similar to the ones
Figure 2. RhoA-induced SIE transcription is driven by Stat3. (A)
RhoA QL (0.1 g DNA) was cotransfected with 0.5 g of either the
human c-fos promoter fragment spanning from nucleotides 362 to
13 subcloned into pBLCAT3 (pfosCAT) or with a mutant in the
SIE element nonresponsive to Stat3 into 293T cells. CAT activity was
determined 24 h posttransfection. Data represent the mean of a
single experiment carried out in triplicate. Similar results were
obtained in three additional independent experiments. (B) Stat3-
mediated SIE transcription induced by RhoA QL. RhoA QL, 0.1 g,
was transiently cotransfected with either 1.0 g of Stat3wt, Stat3F
(DN), or Stat3D (DN) expression vectors along with SIECAT re-
porter. Both Stat3F and Stat3D dominant negative mutants com-
pletely inhibit RhoA QL-induced SIE transcription. (C) Dominant
negative Stat3 do not inhibit SRF activation by RhoA. The same
amounts of RhoAQL and Stat3F/D were transfected as in B along
with 0.5 g of SRECAT reporter. Data shown are representative of
four independent experiments in triplicate. All data shown in this
figure represent the mean of a single experiment performed in
triplicate  SD.
Figure 3. RhoA induces tyrosine phosphorylation and DNA-bind-
ing of Stat3. (A) Tyrosine phosphorylation of Stat3 induced by
RhoA, v-Src, and EGF. RhoA (0.1 g) and v-Src (0.3 g) were
transiently transfected into 293T cells, and total cell extracts were
obtained 24 h posttransfection. As well, cells transfected with the
empty vector were treated with 100 ng/ml EGF (Sigma) for 5 min
before lysis. Whole cell extracts (10 g) were then subjected to
Western blot, with the use of a phosphotyrosine Stat3 (P-Tyr 705)
antiserum. To verify equal loading, the membrane was stripped and
incubated with Stat3 antiserum. (B) RhoA QL induces Stat3 DNA-
binding. 293T cells were transfected with RhoAQL and vSrc, and
24 h posttransfection (0.5% serum), nuclear extracts were obtained
and subjected to EMSA, with the use of the SIE probe. The experi-
ment shown is representative of four independent experiments with
similar results.
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obtained with 293T cells (Figure 1C). Thus, Stat3-dependent
transcriptional activity by RhoA was not restricted to the
HEK-293T cells.
To further confirm the relationship between RhoA and
Stat3, we then used a reporter plasmid constructed by clon-
ing the human c-fos promoter fragment spanning from nu-
cleotides 362 to 13 into pBLCAT3 (pfosCAT). This re-
porter was then mutated by PCR in its SIE element to obtain
a reporter containing a c-fos proximal promoter region non-
responsive to Stat. Consequently, we cotransfected both
these reporter plasmids, pfosCAT and pmSIEfosCAT, along
with the expression vector for RhoA QL (Figure 2A). Tran-
scriptional activation of this c-fos promoter construct was
dependent on the SIE site, because mutation of this element
reduced its stimulation by 80%. It should be noted that the
20% activity left in c-fos transcription corresponds to a four-
fold induction over basal levels, which may correspond to
SRE-dependent transcription.
The above results were generated with the use of the
endogenous Stat3 proteins present in the HEK-293T cells.
We next coexpressed the wild-type version of Stat3 and
RhoA QL along with the SIECAT reporter (Figure 2B). Al-
though expression of Stat3 itself was not capable of inducing
any transcriptional activity of the SIE element, coexpression
of Stat3 with RhoA-QL enhanced SIE-mediated transcrip-
tion. Furthermore, coexpression of RhoA with two dominant
negative mutants of Stat3, with either a mutated tyrosine 705
to phenylalanine (Stat3F), which lacks tyrosine phosphory-
lation, or with impaired DNA-binding activity (Stat3D), re-
spectively, completely inhibited RhoA-mediated SIECAT ac-
tivity. As a control of specificity of inhibition by both Stat3
dominant negative mutants, we tested their ability to inhibit
other Rho-dependent transcriptional signals. As shown in
Figure 2C, neither mutant are capable of inhibiting SRF
activation by RhoA, indicating that their inhibitory action
over SIE-dependent transcription is specific.
RhoA Induces Tyrosine Phosphorylation and DNA
Binding of Stat3 in HEK-293T Cells
Because RhoA can efficiently induce transcriptional activity
of the SIECAT reporter in HEK-293T cells, we investigated
the mechanism of Stat3 activation by RhoA. First, we exam-
ined whether overexpression of RhoA QL could induce ty-
rosine phosphorylation of Stat3. To this end, we transiently
transfected HEK-293T cells with RhoA QL, and 24 h post-
transfection we carried out Western immunoblot analysis
against tyrosine phosphorylation of endogenous Stat3 (Fig-
Figure 4. JAK2 lies downstream of RhoA to induce Stat3 transac-
tivation. (A) Ectopic expression of a dominant negative mutant of
JAK2 (K-E) causes total inhibition of RhoA-induced Stat3-depen-
dent transcription. Indicated amounts of JAK2 KE were cotrans-
fected with RhoA QL (0.1 g) together with the SIECAT reporter. As
a control for JAK2 K-E dominant negative effect, LckDP (1.0 g) was
cotransfected with the same amounts of JAK2 K-E as with RhoA QL.
(B) Dominant negative JAK2 (KE) does not inhibit RhoAQL-depen-
dent activation of SRF. 0.1 g of RhoA QL (0.1 g) and JAK2KE (0.5
g) were transfected as shown, along with 0.5 g of SRECAT
reporter plasmid. (C) Tyrphostin-based JAK2 specific inhibitor, AG-
490, partially inhibits SIECAT reporter activity induced by RhoA
Figure 4 (cont). QL. 293T RhoA QL transfectants were treated with
increasing amounts of DMSO solvent or AG-490 (1, 10, and 20 M)
for 16 h. Data shown for parts A and B represent the mean of a
single experiment carried out in triplicate  SD. Both results shown
are representative of three independent experiments. (D) RhoA QL
induces tyrosine phosphorylation of JAK2. Immunoprecipitation
with an anti-JAK2 antibody of whole cell extracts from quiescent
293T cells transfected with an expression vector for JAK2 or cotrans-
fected with RhoA QL and JAK2 was carried out as described in
EXPERIMENTAL PROCEDURES. After SDS-PAGE and transfer to
PDVF membrane, tyrosine phosphorylation was detected with an
anti-P-Tyr antibody. Similar loading and immunoprecipitation was
determined with the use of an anti-JAK2 antibody.
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ure 3A). Analysis of whole cell extracts with the use of a
phosphotyrosine-specific Stat3 (Tyr 705) antibody revealed
tyrosine phosphorylation of Stat3 in RhoA-transfected cells
to a similar extent as that observed with transfection of v-Src
or cells treated with EGF. In keeping with the above results,
nuclear extracts of RhoA QL transfected HEK-293T cells
were subjected to electrophoretic mobility shift assays
(EMSA) with the use of the SIE element of the c-fos promoter
as a Stat3 DNA binding specific probe. Both RhoA QL and
v-Src induced Stat3 DNA binding to the SIE probe, hence
causing a shift of mobility (Figure 3B), an indication of Stat3
activation. Hence RhoA QL induces both tyrosine phosphor-
ylation of Stat3 and its consequent DNA binding.
JAK2 and a Src Family Kinase Member Mediate
Transcriptional Activity of the SIE Element Induced
by RhoA
Given that RhoA induces tyrosine phosphorylation, DNA
binding, and transcriptional activity of Stat3, we then as-
sessed whether JAK2 could be involved in RhoA-induced
Stat3 activation. To verify this, we used both a tyrphostin-
derived chemical inhibitor specific to JAK2 (AG-490), and a
dominant negative mutant of this kinase with a lysine (K) to
glutamate (E) mutation at residue 899 (JAK2-KE). Cotrans-
fection of JAK2-KE mutant together with RhoA QL in 293T
cells completely inhibits SIECAT reporter activity induced
by both RhoA in a dose-dependent manner (Figure 4A). As
a positive control of inhibition, JAK2 KE was cotransfected
with LckDP at the same doses used with RhoA QL (Figure
4A). Inhibition of JAK2KE is specific to Stat3-dependent
transcription, because it does not inhibit SRF activation by
RhoA (Figure 4B). In addition, treatment with different con-
centrations of AG-490 of HEK-293T cells transfected with
RhoA along with the SIECAT reporter led to 60% inhibi-
tion of reporter activity (Figure 4C). Thus, both results
strongly suggest that JAK2 is a key component in RhoA-
induced Stat3 transcriptional activation.
We next investigated whether tyrosine phosphorylation of
JAK2 is indeed triggered by RhoA QL transfection. As
shown in Figure 4D, immunoprecipitation of JAK2 with a
specific anti-JAK2 antibody and subsequent Western blot
analysis using a general antiphosphotyrosine antibody show
a prominent tyrosine-phosphorylated band in RhoA QL-
transfectants extracts versus control cells, which corre-
sponds to JAK2.
Because both RhoA, v-Src, and LckDP induce Stat3 acti-
vation in this cellular system, we studied whether there is
Figure 5. A Src Family Kinase member synergistically cooperates
with and acts downstream of RhoA QL in Stat3 activation. (A) c-Src
inhibitor PP1 causes a 70% inhibition of RhoA QL-induced Stat3-
dependent transcription. 293T cells were transfected with either
pcDNA3B or RhoA QL (0.1 g) together with the SIECAT reporter
(0.5 g). Twenty hours after transfection, DMSO (2 l) or increasing
concentrations of PP1 were added (1, 10, and 20 M) and incubated
for 4 h. Cells were then lysed, and CAT activity was measured. (B)
PP1 does not inhibit SRF activation by oncogenic RhoA. RhoAQL
was cotransfected with SRECAT reporter, and cells were treated
with PP1 as in A. Data in A and B represent the mean of a single
experiment  SD carried out in triplicate and is representative of
Figure 5 (cont). three independent experiments. (C) RhoA QL
promotes tyrosine phosphorylation of residue 418 of a member of
the Src-FK. Ten micrograms of total extracts from quiescent 293T
RhoA QL transfectants and from control cells treated and untreated
with EGF was subjected to SDS-PAGE. Immunoblot was carried out
with a specific antibody against Tyr-418 of the family of Src kinases
(-SrcFKY418). The experiment shown is from a single experiment
carried out in triplicate  SD and is representative of three inde-
pendent results. (D) Same blot as in B was blotted against anti-Lck
specific antibody. (E) Wild-type Lck (c-Lck) synergizes with RhoA
QL to promote Stat3 activation. Indicated amounts of c-Lck were
cotransfected with oncogenic RhoA (0.1 g) along with the SIE
reporter. CAT activity was determined 24 h posttransfection. The
result shown is representative of three independent experiments.
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any functional interaction between both these proteins and
RhoA, as described for other members of the Ras superfam-
ily of GTPases. PP1, a specific inhibitor for c-Src family
kinases, was used to verify whether RhoA-mediated Stat3
activation is dependent on a member of this family of ki-
nases. Treatment of RhoA transfectants with PP1 inhibits
SIECAT transactivation by 60–70%, consistent with placing
an Src family member downstream of RhoA, necessary for
Stat3 activity (Figure 5A). No effect is observed with a NF-B
responsive reporter (our unpublished results) and an SRF-
dependent element (SRE-CAT) under identical inhibitory
conditions, indicating that this effect is specific for Stat3
activation by RhoA (Figure 5B).
In the same context, we then investigated whether c-Src
could lie downstream of RhoA in Stat3 activation. To this
end, we tested the ability of RhoA QL to promote tyrosine
phosphorylation of residue 418 of human c-Src, which is
conserved in all members of this family and is essential for
their activation. As shown in Figure 5C a prominent band
appears in extracts obtained from RhoA QL-transfected
cells, as well as EGF-treated 293T cells. However, this band
migrates in denaturing polyacrylamide gels to an apparent
molecular weight that is lower of that of c-Src, indicating
that most probably it does not correspond to c-Src. In fact,
subsequent immunobloting of the same membrane with a
c-Src–specific antibody revealed that this band does not
represent c-Src (our unpublished results). Thus, we searched
for other members of the Src family as potential mediators of
Stat3 activation by RhoA. A negative result was obtained
when Lyn was tested (our unpublished results). However,
when an Lck-specific antibody was used, two bands were
detected that matched the phospho-specific bands detected
with the anti–P-Tyr antibody specific against Src family
kinases (Figure 5D).
To further investigate the possible involvement of Lck in
Stat3 activation, we performed experiments of transient ex-
pression of RhoA with or without Lck. As shown in Figure
5E, expression of wild-type Lck itself fails to increase
SIECAT activity. However, when Lck was cotransfected
with oncogenic RhoA, a significant increase in Stat3 activity
was observed with respect to RhoA alone (Figure 5E). Fur-
thermore, coexpression of a dominant negative mutant
RhoA (N19) fails to inhibit LckDP-stimulated SIE transcrip-
tion, whereas completely inhibiting SRF stimulation by 20%
fetal calf serum or lysophosphatidic acid (our unpublished
results). These results demonstrate a functional cooperation
of RhoA and wild-type Lck for Stat3 activation. Further-
more, they also suggest that Lck might be placed down-
stream of RhoA in this signaling cascade.
Serine Phosphorylation of Stat3 by Rho AQL Is
Essential for Its Full Activity and Is Exerted by a
MEKK1/JNK1 Pathway
Recent studies have suggested that phosphorylation of
serine 727 of Stat3 upon diverse stimuli might be an essential
event for the modulation of its activity. Thus, we tested
whether oncogenic RhoA could be inducing serine phos-
phorylation of Stat3 in 293T cells with the use of a phospho-
specific antibody that only recognizes its serine phosphory-
lated form. As shown in Figure 6, both EGF and RhoA QL
lead to phosphorylation of Stat3 on serine 727 to a similar
extent.
Because previous studies have related Stat3 modulation
with the ERK1, p38, and JNK/SAPK kinases, we investi-
gated the possible role of these MAP Kinases signaling
cascades in the transcriptional activation of the SIE element
by RhoA. To this end, we cotransfected the expression vec-
tor of RhoA QL, along with SIECAT plasmid and treated the
cells with the specific MEK1 inhibitor, PD98059 (Figure 7A).
No effect on SIE transcriptional activation was obtained in
PD98059-treated cells, whereas full inhibition of ERK1/2
(p42/44) serine/threonine phosphorylation by EGF was
achieved under similar conditions (Figure 7B). This is not
surprising because RhoA QL fails to activate MAPK in this
cellular system, as in others (Figure 7C). Equal loading was
detected with the use of an anti-MAPK antibody (our un-
published results).
A similar experiment was carried out with the use of the
p38 specific inhibitor, SB203580 (Figure 7D). No effect in SIE
activity after p38 inhibition was observed in RhoA transfec-
tants. Similarly, coexpression of RhoA QL and a dominant
negative mutant MKK6 had no effect over SIE transcrip-
tional levels induced by RhoA, further indicating that this
MAPK pathway is not necessary for Stat3 activation by
RhoA (our unpublished results). As a control of inhibitor
action, we carried out a kinase assay with the use of purified
GST-ATF2 as a substrate to p38. As shown in Figure 7E, full
inhibition of UV-induced p38 activation was achieved upon
conditions similar to those used in RhoA-induced activation
of Stat3. Despite the very slight increase in Ser/Thr phos-
phorylation of p38 in RhoA QL transfectants, this phosphor-
ylation is not relevant to Stat3 activation (Figure 7F). Equal
loading was verified with an antibody specific to p38 (our
unpublished results). Thus, RhoA involves neither MAPK/
ERK nor p38 in Stat3 activation.
Finally, we sought the role of the JNK/SAPK pathway in
Stat3 activation by RhoA. The expression vector for RhoA
was cotransfected with the cDNAs for MEKK1 or a kinase
dead mutant with dominant negative properties termed
MEKK1-K/R, along with the SIECAT reporter in HEK-293T
cells. Wild-type MEKK1 enhanced SIE transcriptional activ-
ity induced by RhoA by fourfold, whereas its kinase dead
mutant caused a 70% decrease in RhoA SIE-induced tran-
scriptional activity (Figure 8A).
Figure 6. RhoA induces serine 727 phosphorylation of Stat3 in
293T cells. RhoA QL and pcDNA3B were transfected, and 24-h
posttransfection whole cell extracts were obtained for Western blot-
ting. Control pcDNA3B-transfected cells were untreated or treated
with 100 ng/ml EGF (5 min). Ten micrograms of total protein was
subjected to SDS-PAGE, transferred to PDVF membrane, and im-
munoblotted with antiphosphoserine-Stat3 antiserum. Equal load-
ing was verified with the use of a specific Stat3 antibody (B). Similar
results were obtained in four independent experiments.
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Activation of the JNK/SAPK cascade by Rho GTPases is
cell specific. In this sense, Rac1 and Cdc42 but not RhoA
activate JNK in COS-7 cells and NIH3T3, whereas in HEK-
293T cells, RhoA and to a lesser extent Cdc42 but not Rac1
activate this cascade (Coso et al., 1995; Teramoto et al., 1996).
As previously mentioned, RhoA can also mediate JNK ac-
tivity in human epithelial A549 cells (Roberts et al., 1998).
Accordingly, cotransfection of Gal4-luc/Gal4-jun (a reporter
system indicative of JNK activity) with RhoA QL indeed
shows JNK activity (our unpublished results). To demon-
strate a functional relationship between JNK1 and Stat3
downstream of RhoA, we coexpressed wild-type JNK1 and
constitutively active RhoA QL and measured SIECAT tran-
scriptional activity. JNK1 caused more than a fivefold syn-
ergism in a dose-dependent manner with RhoA QL to pro-
mote SIE-dependent transcription, hence confirming the role
of JNK1 in RhoA-mediated Stat3 activation (Figure 8B). In
addition, expression of a dominant negative mutant form of
the scaffold protein JIP-1 (Dickens et al., 1997) completely
inhibited RhoA-induced SIE-dependent transcriptional ac-
tivity, further indicating that the JNK cascade is essential for
full Stat3 activity in the context of oncogenic RhoA (Figure
8B).
The Effector Region of RhoA Is Necessary for Full
Activation of Stat3
Mutations within the effector loop region have constituted a
valuable tool to interconnect the different pathways trig-
gered by small GTPases with specific downstream effects
(Sahai et al., 1998; Zohar et al., 1998). A set of different RhoA
mutants in the effector region (see MATERIALS AND
METHODS) was tested for their ability to activate the
SIECAT reporter. Two mutants tested, RhoAQL (F39E) and
(F39L), show complete impaired ability to promote SIECAT
transcription, and a third mutant (V35D) displayed 50%
Figure 7. Neither MEK1 nor p38
signaling pathways are involved in
RhoA-mediated Stat3 activation.
(A) MEK1 specific inhibitor
PD98059 does not cause any effect
in RhoA QL-induced SIECAT re-
porter activity. Control vector or its
derivative RhoA QL were cotrans-
fected into 293T cells along with
the SIECAT reporter. Eight hours
before lysis, cells were treated with
PD988059 at a final concentration
of 50 M. CAT activity was then
assessed as described in EXPERI-
MENTAL PROCEDURES. The
data shown here represent the
mean of a single experiment car-
ried out in triplicate  SD. The
same experiment was carried out
four times with similar results. (B)
PD98059 inhibits EGF-induced
MAPK activation in HEK293T
cells. Parallel to the experiment
above, quiescent cells (24 h in 0.5%
FBS) were stimulated with EGF
(100 ng/ml) or EGF and PD98059
(50 M) for 5 min. Whole extracts
were obtained, and 10 g of pro-
tein was used for SDS-PAGE.
Membranes were incubated with
antiphospho-MAPK mAb. Same
results were obtained in four inde-
pendent results. (C) RhoA QL does
not activate ERK1/2 in 293T cells.
Same extracts as in A, were sub-
jected to SDS-PAGE and trans-
ferredtoPDVFmembranes. Immu-
nobloting was carried out with
antiphospho-MAPK antibody. The
result shown is representative of
three independent results. (D) p38-
specific inhibitor SB203580 (Calbiochem) does not alter RhoA-mediated Stat3-dependent transcription. RhoA QL was cotransfected with the SIECAT
reporter. Twenty-four hours after transfection cells were treated with SB203580 at a final concentration of 20M for 6 h. CAT activity was measured. Data
shown are the mean of a single experiment done in duplicate  SD. Similar results were obtained in four independent experiments. (E) p38 inhibitor,
SB203580, efficiently inhibits p38 kinase activity induced by UV light. (F) RhoA QL does not affect p38 activity. Ten micrograms of total extracts from 293T
cells unstimulated or stimulated with UV or transfected with oncogenic RhoA QL (0.1 g) was subjected to SDS-PAGE and transferred to PDVF
membranes. Immunoblots were incubated with phospho-specific p38 antibody. Result shown is representative of two independent experiments.
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activity of SIE transcription, whereas a mutant with a D45Q
mutation retained full capacity to induce Stat3-dependent tran-
scription when compared with RhoA QL (Figure 9A). Accord-
ingly, both F39L and F39E mutants have lost the capacity to
promote tyrosine phosphorylation on residue 418 of Src Family
Kinase member, whereas D45Q mutant induced similar levels
of phosphorylation of Src Family Kinase member as those
induced by the unmutated RhoAQL. V35D mutant showed a
partial activation of both phosphorylation and Stat3 transcrip-
tional activity (Figure 9B). Finally, a complete correlation be-
tween Stat3 activation and JNK activation was also found.
Although a drastic reduction of both JNK and Stat3 activity
was achieved with F39L and F39E, the V35D mutation only
partially inhibited JNK activation, which would also account
for the partially impaired ability of this mutant to promote
SIE-dependent transcription (Figure 9C). In keeping with the
above results, D45Q mutant showed JNK activation to the
same extent as that of RhoA QL. Thus, RhoA activation of Stat3
is dependent on its effector binding region, which is necessary
for its ability to promote both tyrosine and serine phosphory-
lation of Stat3.
RhoA and Stat3 Cooperate for Oncogenic
Transformation of the Human HEK-293T Cells
To investigate whether activation of Stat3 had any effect on
the biological function of RhoA, a system for testing Stat3
influence in the oncogenic transformation mediated by
RhoA was set up as a biological read out. Transient trans-
Figure 8. MEKK1/JNK1 signaling lies downstream of RhoA QL and
is involved in Stat3 signaling. (A) Ectopic expression of wild-type
MEKK1 or its dominant negative mutant, MEKK1KR, synergizes and
inhibits respectively Stat3-dependent transcription induced by RhoA
QL. 293T cells were cotransfected with either 0.5 g of MEKK1 or
MEKK1 KR together with RhoA QL (0.1 g) along with the SIECAT
reporter. Twenty-four hours after transfection, cells were lysed, and
CAT activity was measured. (B) JNK1 pathway is essential for Stat3
activation by oncogenic RhoA. Wild-type JNK1 (1.0 g) or dominant
negative JIP-1 were each cotransfected with RhoA QL (0.1 g) and
control vector along with the SIECAT reporter. CAT activity was
assayed 24 h posttransfection. All data shown are the mean of a single
experiment carried out in triplicate  SD. Similar results for all data
shown were obtained in three independent experiments.
Figure 9. The effector binding region of RhoA is necessary for Stat3
activation. (A) Mutations of residue 39 or 35 within the effector region
of RhoA completely or partially impair Stat3 activation, respectively.
The indicated mutants were cotransfected along with the SIECAT
reporter, and CAT activity was assayed 24 h posttransfection. (B)
RhoA, F39L, and F39E mutants fail to induce tyrosine phosphorylation
of a SrcFK member activated by oncogenic RhoA, whereas V35D is
capable of doing so partially. Western blot analysis of 10 g with
anti-SrcFK Y418, of whole cell extracts from quiescent 293T cells trans-
fected with the indicated expression vectors, was carried out. Equal
loading was verified after stripping of the membrane with an anti-Lck
antibody (our unpublished results). (C) V35D mutant has a partially
impaired ability to promote JNK1 activation. Extracts from quiescent
293T cells transfected with the indicated RhoA mutant’s expression
vectors along with the Gal4-luc/Gal4-Jun reporters were assayed for
luciferase activity. All data shown in parts (A) and (C) are the mean of
a single experiment carried out in triplicate  SD and are representa-
tive of nine independent experiments.
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fection experiments of the human HEK-293T cells were per-
formed as described above with the use of either RhoA alone
or in combination with wild-type Stat3, dominant negative
Stat3 mutants, Stat3F, and Stat3D as well as dominant neg-
ative mutant JIP1 (Figure 10A). Transfected cells were then
plated on soft-agar plates, and growth of anchorage-inde-
pendent clones was estimated after 3 weeks. Expression of
RhoA QL is sufficient to induce a 2.7-fold increase in the
number of colonies. Also, an increase in the mean size of the
colonies was observed with respect to control cells, as de-
termined by their relative spherical volume. Expression of
Stat3wt, Stat3F, Stat3D, or JIP1DN alone had no influence
over background levels. However, coexpression of Stat3wt
with RhoA QL resulted in a further increase of approxi-
mately fourfold in the number of colonies over RhoAQL
alone. As well, an increased range in colony volume in RhoA
transfectants combined with Stat3 is observed with respect
to control colonies (our unpublished results). Furthermore,
combinations of both Stat3 dominant negative mutants (F
and D) or JIP1DN with RhoA QL, reverse the oncogenic
potential of the latter back to background levels (Figure
10A). This suggests that both tyrosine and serine phosphor-
ylation of Stat3 are essential to induce full effects in the
context of oncogenic signaling.
In addition, the ability of RhoA mutants, F39E, F39L, D45Q,
and V35D, to promote anchorage-independent growth was
tested (Figure 10B). Both mutants that fail to activate Stat3
(F39L and F39E) do not promote significant growth in soft-
agar. However, RhoAQL-D45Q and RhoAQL-V35D promoted
anchorage-independent growth but to a lesser extent than on-
cogenic RhoAQL. Thus, these results further suggest that Stat3
might be an important player in RhoA-mediated oncogenic
transformation.
Taken together, these results demonstrate that simulta-
neous tyrosine and serine phosphorylation of Stat3 plays an
important role in the oncogenic activity of RhoA.
DISCUSSION
It is well established that Stat3 activation is based on the
phosphorylation of a single tyrosine residue at position 705
(for reviews see Darnell, 1997; and Hoey and Grusby, 1999).
This phosphorylation event enables cytoplasmic Stat3 to
homo- or heterodimerize via its SH2 domains, to subse-
quently translocate to the nucleus, and to interact with spe-
cific DNA elements, thereby promoting gene transcription.
At least two tyrosine kinases have been identified as being
directly responsible for Stat3 phosphorylation at tyrosine
residues. Cytokine receptor oligomerization brings JAKs in
juxtaposition, permitting their cross-phosphorylation and
subsequent activation. These tyrosine-phosphorylated resi-
dues then constitute docking sites for the SH2 domains for
the different Stats, which once recruited become phosphor-
ylated on a single tyrosine residue by JAKs. Receptor ty-
rosine kinases dimerize upon ligand binding and transphos-
phorylate each other at tyrosine residues that work as
attachment sites for different proteins that contain SH2 do-
mains. For instance, upon EGF stimulation, c-Src is rapidly
recruited to the dimerized ErbB receptor via its SH2 do-
mains, where it can interact with Stat/ErbB receptor com-
plexes, hence phosphorylating the transcription factors in a
JAK-independent manner (Monilola et al., 1999). In keeping
with this, a recent report indicates that upon EGF binding,
EGFR activates c-Src through RalA to induce Stat3 activa-
tion, providing evidence that this growth factor induces
Stat3 activation through different mechanisms depending on
which receptor it may bind to (Goi et al., 2000). Here we
demonstrate that RhoA and to a lesser extend Cdc42 but not
Rac1, activate Stat3 transcriptional function by triggering a
novel pathway that involves a member of the Src family of
kinases (SrcFK) and JAK2. The role of JAK2 in small GT-
Pases of the Rho family might be a common event, because
Rac1 also uses this tyrosine kinase to induce tyrosine phos-
phorylation of Stat3 in other cellular systems (Simon et al.,
2000). In the past years, several works have studied the
functional relationship between Src and RhoA in critical
cellular functions such as cell growth, cytoskeletal organiza-
Figure 10. Stat3 is necessary for contact-independent growth of
RhoA-transfected 293T cells in soft-agar. (A) Stat3wt, Stat3F (DN),
Stat3D (DN), or JIP-1 (DN; 1.0 g each) modulate anchorage-inde-
pendent growth of RhoA QL-transfected 293T cells. Cells, 8  105,
were transfected with the indicated expression vectors and main-
tained in optimal serum conditions for 24 h posttransfection. After
trypsin-EDTA treatment, 4  104 cells were seeded in a soft agar
base and incubated for 21 d. Although RhoA QL and Stat3 synergize
to promote anchorage-independent growth, both Stat3 mutants (F
and D) completely abrogate RhoA QL oncogenic potential. The
same inhibitory effect to the one observed with dominant negative
mutants Stat3 was obtained with JIP-1 (DN). No effect was observed
with Stat3wt, Stat3F, Stat3D, or JIP-1 alone. (B) RhoA mutants
QL-F39E and QL-F39L, which fail to activate Stat3, do not induce
anchorage-independent growth in soft agar. Data shown represent
a single experiment carried out in triplicate. The result shown is
representative of seven independent experiments for A and two
independent experiments for B, with similar results.
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tion, and transformation. Evidence for placing RhoA both
upstream and downstream of c-Src activation has been re-
ported (Nagao et al., 1999; Nozu et al., 1999; Tominaga et al.,
2000). We have observed a dependence of RhoA on SrcFK
activity to promote Stat3 activation, because a chemical in-
hibitor of this family of kinases greatly reduces transcrip-
tional activation of Stat3 induced by RhoA. It is clear al-
though that neither c-Src nor c-Lyn mediate this process,
because oncogenic RhoA fails to activate either of them. By
contrary, an antibody raised against c-Lck recognizes the
phosphorylated band that appears in extracts of RhoA-
transfectants. On the other hand, when c-Lck is coexpressed
with RhoA QL, Stat3 activity is enhanced more than twofold
with respect to RhoA alone. Whether other members of the
SrcFK can also contribute to this effect remains to be eluci-
dated. Experiments in our group are currently in progress to
address this issue.
Stat3 and Stat1 are susceptible to serine phosphorylation on
a single serine residue (Ser-727) by members of the MAPK, p38,
and MEKK1 signaling cascades (Wen et al., 1995; Ceresa and
Pessin, 1996; Ceresa et al., 1997; Chung et al., 1997; Wen and
Darnell, 1997). Yet, depending on the particular stimulus,
serine phosphorylation is capable of either potentiating Stat3
transcriptional activity or to negatively regulate it, without
affecting its DNA binding affinity. Here we unambiguously
demonstrate that serine phosphorylation of Stat3 by RhoA is
executed by the JNK pathway, whereas the ERKs or p38 ki-
nases are not involved. Furthermore, we demonstrate that not
only RhoA induces activation of Stat3 by JNK phosphorylation
of Ser-727, but also that this event cooperates with tyrosine
phosphorylation for full transcriptional activation. Moreover,
suppression of either event alone is sufficient to impair activa-
tion of Stat3 and RhoA-induced transformation. However, the
precise mechanism by which RhoA activates these two con-
verging signaling cascades remains to be fully elucidated. Re-
cently, Simon et al. (2000) have described that Rac1 interacts
directly with Stat3 through its effector domain, and is capable
of inducing both its tyrosine and serine phosphorylation. Al-
though we observe that Stat3 activation by RhoA is dependent
on the effector loop region (Figure 9), we have not tested
whether both proteins interact directly or via other proteins.
Much is known about the physiological roles of Stats
signaling mediated by cytokines (Darnell, 1997; Hoey and
Grusby, 1999). Stats are implicated in ligand-dependent
growth stimulation or differentiation as well as in antipro-
liferative effects. In recent years, Stats have been implicated
in growth disregulation and tumorigenesis (Garcia and Jove,
1998; Bromberg et al., 1999; Ram et al., 2000). Cell lines stably
transformed with different oncogenes related to tyrosine
kinase receptors show constitutive activation of Stat3 pro-
teins (Garcia and Jove,1998). Specifically, Stat3 mediates and
is necessary for the transforming phenotype of Src oncopro-
tein and members of the Src-family of kinases (Cao et al.,
1996; Liu et al., 1998; Lund et al., 1999). Constitutively active
Stat3 is also observed in a number of different human tu-
mors and cell lines derived from human tumors. Moreover,
a constitutively active mutant Stat3 is capable of transform-
ing cultured cell lines and to induce tumors in nude mice,
hence constituting an oncoprotein in itself independent of
tyrosine kinase signaling (Bromberg et al., 1999).
Rho GTPases have been shown to be oncogenic (Ballestero
et al., 1991; Perona et al., 1993; del Peso et al., 1997; Lacal.,
1997; Lin et al., 1999; Turkson et al., 1999), but the knowledge
of their precise mechanism for oncogenic transformation still
contains many gaps. Indeed, transcriptional regulation in-
duced by Rho proteins and their oncogenicity could be
intimately related. In this report, we show strong evidence
for such a direct link, because RhoA-induced transformation
depends on Stat3 transcriptional activity, providing a new
clue for the ability of Rho proteins to induce transformation.
We demonstrate that both tyrosine and serine phosphoryla-
tion of Stat3 induced by RhoA are required to achieve full
Stat3 activation. Furthermore, cooperation of RhoA and
Stat3 synergies for transformation of human HEK-293T cells.
A significant increase in both the number and size of an-
chorage-independent colonies, a landmark for tumorigenic-
ity, indicates that Stat3 is an important player in transfor-
mation mediated by RhoA. Inhibition of tyrosine
phosphorylation by a mutated Stat3 (F) proves that phos-
phorylation at this residue is essential for RhoA-induced
transformation. Interestingly, because dominant negative
JIP1 completely inhibits Stat3 activation by RhoAQL and it
abolishes the ability of RhoA transfectants to grow under
anchorage-independent conditions, it can be concluded that
serine phosphorylation of Stat3 might also be necessary for
RhoA-mediated transformation.
These results may also be relevant to the carcinogenesis
process in humans. It has been recently demonstrated that
primary human HEK cells need to be genetically altered by
al least three concurrent events in order to become fully
tumorigenic (Hahn et al., 1999). Our results are consistent
with that of Hahn et al., because HEK-293T carry both E1A
and Large T antigen, in that these alterations confer very low
growth properties in soft agar and fail to induce tumorige-
nicity in syngeneic mice even upon injection of 2  106 cells
(our unpublished results). However, additional mutations in
signaling pathways involving Rho GTPases, instead of Ras,
seem to be sufficient for anchorage-independent growth.
Our results directly implicate Stat3 in RhoA transformation.
However, further research will be needed to clarify its relation-
ship with other transcription factors, such as NF-B, previously
reported to be implicated in Rho-mediated transformation (Lin
et al., 1999). Furthermore, the possible role of Stat3 in transfor-
mation should be determined in human tumors known to
contain high levels of RhoA or Rac1 (Fritz et al., 1999). Also the
involvement of other genes responsive to Stat3 regulation, such
as Bcl-XL, cyclin D, p21WAF1/CIP1, or p19INK4d, should be
investigated (Karni et al., 1999; Kiuchi et al., 1999; Narimatsu et
al., 1997; O’Farrel, et al., 2000). Finally, the relationship between
these transcriptional pathways with both the regulation of the
cytoskeleton and cell adhesion by oncogenic RhoA should be
determined. Although these distinct effects and functions have
been commonly treated as independent events, an increasing
amount of evidence points out to an intimate cooperation of
these to promote oncogenic transformation (Aznar and Lacal,
2001a, 2001b).
There is strong evidence suggesting that transformation
by Ras oncogenes require Rho GTPases (Qiu et al., 1995a,
1995b, 1997; Osada et al., 1997; Nur-E-Kamal et al., 1999;
Philips et al., 2000). Because Ras oncogenes are directly in-
volved in at least 25–30% of all human cancers, it places the
Rho/Stat3 signaling pathway as a possibly important player
in human carcinogenesis. As well, it might play a relevant
role in tumors where RhoA (and possibly other Rho GT-
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Pases) is overexpressed independently of Ras. Furthermore,
the link between Rho- and Src-dependent signaling suggests
that Rho may participate in pathways relevant to human
cancer other than ras oncogenes. At last, these results could
be relevant for novel therapeutic strategies that target Stat3
where Ras and Rho proteins are an issue.
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